Debate box

Article

As the Health Information Technology Policy Committee (HITPC) prepares the stage two definition of “meaningful use” of EHRs, there is ongoing debate over the perceived long-term benefits versus the immediate expenses-both in terms of money and time. This week we discuss the current status of EHR implementation and incentives.

EHRs and Meaningful Use 

 

 

 

As the Health Information Technology Policy Committee
(HITPC) prepares the stage two definition of “meaningful use”
of EHRs, there is ongoing debate over the perceived long-term
benefits versus the immediate expenses-both in terms of 
money and time. This week we discuss the current status
of EHR implementation and incentives.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content